ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "American College of Rheumatology Criteria"

  • Abstract Number: 1654 • ACR Convergence 2021

    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

    Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
  • Abstract Number: 1733 • ACR Convergence 2021

    Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

    Martin Aringer1, Ian N. Bruce2, Richard Furie3, Eric Morand4, Emmanuelle Maho5, Catharina Lindholm6 and Raj Tummala7, 1University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 4Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
  • Abstract Number: 1746 • ACR Convergence 2021

    Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

    Thomas Dörner1, Ronald Van Vollenhaven2, Andrea Doria3, Bochao Jia4, Damiano Fantini4, Jorge Ross Terres4, Maria Silk5, Stephanie de Bono4, Peter Fischer6 and Daniel Wallace7, 1Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, 2University Medical Center, Amsterdam, Netherlands, 3University of Padova, Padova, Italy, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Carmel, IN, 6Eli Lilly and Company, North Easton, MA, 7Cedars-Sinai, Los Angeles, CA

    Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
  • Abstract Number: 1801 • ACR Convergence 2021

    The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis

    Elaine Husni1, Sona Kamat2, Keri Stenger3, Rebecca Bolce3, Thorsten Holzkaemper4, Cameron Helt3, So Young Park3, Jeffrey Lisse5 and Luca Idolazzi6, 1Cleveland Clinic, Cleveland, OH, 2St Louis University, Saint Louis, MO, 3Eli Lilly and Company, Indianapolis, IN, 4Eli Lilly and Company, Bad Homburg, Germany, 5Eli Lilly and Company, Tucson, AZ, 6University of Verona, Verona, Italy

    Background/Purpose: It is important to understand how to select among the multiple treatment options for active psoriatic arthritis (PsA). Since individual patient domains may influence…
  • Abstract Number: 1888 • ACR Convergence 2021

    Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD

    Gözde Kübra Yardımcı1, Bayram Farisogulları2, Gizem Ayan1, Levent Kilic1, Sule Apraş Bilgen1 and Omer Karadag3, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, 3Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey

    Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…
  • Abstract Number: 1511 • ACR Convergence 2020

    Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort

    Melissa Munroe1, Kendra Young2, Jill Norris3, Joel Guthridge4, Diane Kamen5, Timothy Niewold6, Gary Gilkeson7, Michael Weisman8, Mariko Ishimori9, Daniel Wallace10, David Karp11, John Harley12 and Judith James13, 1Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, 2University of Colorado Denver, Aurora, CO, 3Colorado School of Public Health, Aurora, CO, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Medical University of South Carolina, Charleston, SC, 6NYU School of Medicine, New York, NY, 7Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 8Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, 9Cedars-Sinai Medical Center, Los Angeles, CA, 10Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, 11UT Southwestern Medical Center, Dallas, TX, 12Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, 13Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
  • Abstract Number: 1609 • ACR Convergence 2020

    The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia

    Khalid Almutairi1, Johannes Nossent1, David Preen1, Helen Keen1, Katrina Rogers2 and Charles Inderjeeth1, 1The University of Western Australia, Perth, Western Australia, Australia, 2Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

    Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…
  • Abstract Number: PP01 • ACR Convergence 2020

    Impacting Change Through Facilitation and Advocacy for Lupus

    Monica Watson1, 1Lupus Foundation of America, Darby, PA

    Background/Purpose: My story started as one of disbelief in 2009 with my Lupus diagnosis. How could a woman in the prime of her career be…
  • Abstract Number: 0005 • ACR Convergence 2020

    Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists

    Bella Mehta1, Deanna Jannat-Khah2, Carol Mancuso3, Anne Bass1, Carine Moezinia4, Allan Gibofsky3, Susan Goodman5 and Said Ibrahim6, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York City, NY, 3Hospital for Special Surgery, New York City, 4Hospital for Special Surgery, New York, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Weill Cornell Medicine, Cleveland, OH

    Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
  • Abstract Number: 0351 • ACR Convergence 2020

    Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients

    Laure Gossec1, Elke Theander2, Soumya Chakravarty3, Paul Bergmans4, Iris Lin5, Wim Noël6, Stefan Siebert7 and Josef Smolen8, 1Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 2Janssen Cilag, Lund, Sweden, 3Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, 4Janssen Biostatistics and Medical Affairs, Tilburg, Netherlands, 5Janssen Immunology Global Commercial Strategy Organization, Horsham, 6Janssen Medical Affairs, LLC, Beerse, Belgium, 7University of Glasgow, Glasgow, United Kingdom, 8Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

    Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…
  • Abstract Number: 0359 • ACR Convergence 2020

    Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Soumya Chakravarty2, Robert McLean3, Taylor Blachley3, Toana Kawashima4, Iris Lin5, Jonathan Uy6, Arthur Kavanaugh7 and Alexis Ogdie8, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, 3Corrona, LLC, Waltham, MA, 4Corrona, LLC, Waltham, 5Janssen Immunology Global Commercial Strategy Organization, Horsham, 6Janssen Scientific Affairs, LLC, Horsham, 7UC San Diego Health System, San Diego, CA, 8Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
  • Abstract Number: 0414 • ACR Convergence 2020

    Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Young4, Cristina Burroughs5 and Peter Merkel6, 1University of Kansas Medical Center, Overland Park, KS, 2David Geffen School of Medicine / University of California, Los Angeles, CA, 3Vasculitis Foundation, North Carolina, 4Vasculitis Foundation, Kansas City, 5University of South Florida, Tampa, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cyroglobulinemic vasculitis (CV) and IgA vasculitis are forms of small-vessel vasculitis characterized by immune complex deposition. The purpose of this study was to a)…
  • Abstract Number: 0416 • ACR Convergence 2020

    IgG4-related Retroperitoneal Fibrosis. Retrospective Cohort

    Ernestina Angarola1, Federico Jauk2, Verónica Peuchot3, Maria Orlova1, Melina Valeo2, Javier Pollan1 and Hernán Garcia Rivello2, 1Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Department of Pathology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 3Internal Medicine Research Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

    Background/Purpose: The spectrum of IgG4-related disease (IgG4-RD) includes many diseases that were thought to be confined to a single organ, as the retroperitoneal fibrosis. Many…
  • Abstract Number: 0676 • ACR Convergence 2020

    Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care

    Joshua Gavin1, Yashswee KC2, Evan Dombrosky3, Nehal Shah4 and Youssef Roman4, 1Virginia Commonwealth University School of Medicine, Richmond, 2Virginia Commonwealth University School of Medicine, Henrico, VA, 3Virginia Commonwealth University School of Medicine, Glen Allen, VA, 4Virginia Commonwealth University School of Medicine, Richmond, VA

    Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
  • Abstract Number: 0717 • ACR Convergence 2020

    Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies

    Jelena Vojinovic1, Vyacheslav Chasnyk1, Joke Dehoorne1, Violeta Panaviene1, Jonathan Akikusa2, Tadej Avcin1, Jeffrey Chaitow1, Bernard Lauwerys1, Jordi Antón1, Inmaculada Penades1, Berit Flato1, Alina Boteanu3, Hans-Iko Huppertz1, Juan Jaller1, Daniela Graham4, Cecilia Borlenghi5, Bonnie Vlahos6, Chuanbo Zang6 and Nicolino Ruperto2, 1Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Pfizer, Groton, PA, 5Pfizer, New York, NY, 6Pfizer, Collegeville, PA

    Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology